{"gao_id": "GAO-21-272", "published": "2021-03-31T12:00:00Z", "released": "2021-03-31T08:00:00Z", "summary": "Remdesivir was the first drug approved by the Food and Drug Administration to treat COVID-19 . Gilead Sciences, Inc., originally developed it to treat other viral diseases. We reviewed federal contributions to development of remdesivir and related agency patent rights. As of Dec. 2020, federal funding for preclinical studies and clinical trials involving remdesivir totaled about $162 million. The federal contributions did not result in...", "title": "Biomedical Research: Information on Federal Contributions to Remdesivir", "topics": ["Virology", "Agency evaluations", "Health care", "Pathogens", "Drugs", "Scientists", "Federal contributions", "Public health emergencies", "Federal agencies", "Patent applications", "Intellectual property", "Research and development", "Clinical trials", "Biomedical research", "Federal funds", "License agreements", "Science and Technology", "Disease control", "Intellectual property rights", "Infectious diseases"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-21-272", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-21-272-highlights.pdf"}, {"title": "Full Report (40 pages)", "url": "https://www.gao.gov/assets/gao-21-272.pdf"}, {"title": "Accessible PDF (45 pages)", "url": "https://www.gao.gov/assets/720/713520.pdf"}]}